Trials / Completed
CompletedNCT00852670
ACT-128800 in Psoriasis
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIa Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800, an S1P1 Receptor Agonist, Administered for 6 Weeks to Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Actelion · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy, safety, and tolerability of ACT-128800 in subjects with moderate to severe plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACT-128800 | ACT-128800 administered orally once daily |
| DRUG | Placebo | Matching placebo capsules administered orally once daily |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2009-07-01
- Completion
- 2009-09-01
- First posted
- 2009-02-27
- Last updated
- 2009-11-13
Locations
14 sites across 5 countries: Austria, France, Germany, Hungary, Serbia
Source: ClinicalTrials.gov record NCT00852670. Inclusion in this directory is not an endorsement.